Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2025
Predictors of damage accrual by organ domain in systemic lupus erythematosus
Rheumatology 2025;18:keaf610 Doi: 10.1093/rheumatology/keaf610 Epub ahead of print
Kandane-Rathnayake et al. reported that risk factors for individual organ system damage were highly varied in patients with SLE, and not all factors associated with domain-specific damage were captured by summed systemic lupus international collaborating clinics/american college of rheumatology damage index (SLICC/ACR SDI) for overall organ damage.
November 2025
Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: A multicentre, randomised, double-blind, placebo-controlled trial
Ann Rheum Dis 2025 Doi: 10.1016/j.ard.2025.10.010. Epub ahead of print
Sun et al. provides the first RCT evidence that low-dose belimumab reduces flares in patients with SLE with low-grade disease activity. Authors evaluated the efficacy of low-dose belimumab for disease flare prevention in Chinese patients with low-grade SLE (SELENA-SLEDAI ≤6).
Keywords:
August 2025
Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: A randomised, double-blind, placebo-controlled, Phase II study
RMD Open 2025;11:e005557 Doi:10.1136/rmdopen-2025-005557
Shen N et al. report that iscalimab was clinically effective and generally well tolerated; in addition, it was devoid of the thromboembolic risk, characteristic of Fc active anti-CD40L therapies.